- Open Access
The relationship between oxidized lipoprotein(a) and carotid atherosclerosis in asymptomatic subjects: A comparison with native lipoprotein(a)
© Kotani et al; licensee BioMed Central Ltd. 2011
- Received: 2 August 2011
- Accepted: 4 October 2011
- Published: 4 October 2011
Oxidized lipoprotein(a) (oxLp(a)) can be a more potent marker of atherogenesis than native Lp(a), although Lp(a) is considered to be a risk factor for atherosclerotic diseases. Limited clinical data are available regarding the significance of oxLp(a) in atherosclerotic manifestations. This study aimed to investigate the association between the serum oxLp(a) and carotid artery intima-media thickness (CIMT), in comparison to the serum Lp(a) levels, among asymptomatic subjects.
The atheroscrerosis-related variables including Lp(a) and oxLp(a) were measured in 136 cardiovascular disease-free subjects (61 males and 75 females, mean age of 64 years). The serum oxLp(a) level was quantified using a sandwich ELISA system. The CIMT level was ultrasonographically measured on bilateral carotid arteries.
The median level of Lp(a) was 120 μmol/L, oxLp(a) was 0.06 nmol/L, and CIMT was 0.7 mm, respectively. A simple correlation test showed that the CIMT was significantly and positively correlated with age, systolic blood pressure and oxLp(a) (r = 0.208, P < 0.05). A multiple linear regression analysis revealed that oxLp(a) continued to show a significant and positive correlation with the CIMT (β = 0.202, P = 0.01). Although the similar analyses were conducted for Lp(a), it showed only a weak correlation with the CIMT (r = 0.011, β = 0.041, both P < 0.05).
These results suggest that oxLp(a) may be more closely associated with accelerated carotid atherosclerosis, in comparison to Lp(a), in this population. This finding can be important for obtaining a better understanding of the different atherogenic roles played by oxLp(a) in comparison to Lp(a).
- Multiple Linear Regression Analysis
- Carotid Atherosclerosis
- Confidential Interval
- Subendothelial Layer
- Systemic Arterial Stiffness
The oxidation of lipids and lipoproteins is involved in the pathogenesis of atherosclerosis . Lipoprotein(a) (Lp(a)) contains low-density lipoprotein (LDL)-like moieties, in which the apoB-100 component is covalently linked to the unique glycoprotein, apolipoprotein(a) (apo(a)), and a high circulating level of Lp(a) is considered to be a risk factor for atherosclerotic diseases [2, 3]. While the physiological role of Lp(a) in atherosclerotic diseases remains incompletely understood, the oxidization of Lp(a) may be one of the crucial clues that atherogenesis has occurred. Of note, the existence of oxidized phospholipids on Lp(a) in the circulation has been reported to be strongly associated with coronary artery disease . The earlier studies used an assay system that determines the content of oxidized phospholipids per particle of apoB-100 and primarily per Lp(a), and the results suggested that Lp(a) may participate in the transfer of oxidized phospholipids . We have also identified oxidized Lp(a) (oxLp(a)) in human arteries and blood using an assay system which employs a unique antibody (161E2) to a specific epitope peptide of nine residues (Arg-Asn-Pro-Asp-Ala-Val-Ala-Ala-Pro) from the kringle-IV type 2 of apo(a) (this specific site is hidden on native Lp(a) particles, but appears on Lp(a) in the oxidative milieu) . We have thus already accumulated some data using this oxLp(a) measurement [5–8].
Although earlier experimental studies have revealed that oxLp(a) can have more atherogenic properties than native Lp(a) [5, 9–14], there have so far been only limited clinical studies using the serum oxLp(a) to investigate the association between oxLp(a) and atherosclerotic manifestations. More recently, two clinical studies have been published about this association [6, 8]. One study reported that there was a significant and positive correlation between the serum oxLp(a) and pulse wave velocity index (a measure of systemic arterial stiffness) in hypertensive patients, and this correlation was relatively greater than that between the serum Lp(a) and pulse wave velocity index . In addition, that study reported that the oxLp(a) deposition was histochemically detected, while the native Lp(a) deposition was not, in the coronary calcified areas in patients with myocardial infarction . Another study reported that oxLp(a) was histochemically detected in endothelial cells, similar to native Lp(a), in human carotid and cerebral arteries, and the deposition of oxLp(a), but not native Lp(a), was abundant in the synthetic phase vascular smooth muscle cells in the same arteries . These findings indicate that oxLp(a) can be more potent in the formation of atherosclerosis throughout the early to progressive stages of atherosclerosis than native Lp(a). These findings warranted further evaluation of the significance of oxLp(a) in the clinical settings.
The carotid arterial intima-media thickness (CIMT) is frequently used in the clinic as one of the most representative surrogate measures of cardiovascular disease (CVD) risk [15, 16]. Although we have previously reported a non-significant correlation between the serum oxLp(a) and CIMT, the study population in that report included only healthy young females (mean age: 22 years) all of whom had very low CIMT levels (mean: 0.40 mm) ; therefore, it was difficult to assess the correlation. Taking the background into account, the aim of the present study was to investigate the relationship between the levels of serum oxLp(a) and CIMT, in comparison to the serum Lp(a) levels, among asymptomatic middle-aged and older subjects.
A total of 136 Japanese subjects (mean age; 64 years, range; 40-86 years) were enrolled in this study. The eligibility criteria were: 1) asymptomatic, 2) without pregnancy, 3) neither regularly drank alcohol nor currently smoked, 4) drug-free (including oral contraceptives and over-the-counter drugs such as antioxidant agents), 5) without any history of cardio/cerebrovascular, thyroid, kidney or liver diseases. The Jichi Medical University ethics committee approved the study, and each subject gave informed consent.
The body mass index (BMI), seated systolic blood pressure (SBP)/diastolic blood pressure (DBP) in the upper-arm, plasma glucose and serum lipids/lipoproteins, including Lp(a) and oxLp(a), were measured. Blood was sampled from the antecubital vein after an overnight fast. The samples were immediately evaluated for glucose and lipids, and the serum samples for evaluation of Lp(a) and oxLp(a) were frozen at -80°C until they were used for measurement (within 3 months). Glucose and lipids (LDL cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C] and triglycerides [TG]) were measured enzymatically, and the serum Lp(a) was measured by an ELISA system (Shino-test Co. Ltd., Japan) . The assay system for Lp(a) uses only a monoclonal antibody to a non-repeated segment of apo(a), kringle-IV type 5, as both the solid-phase antibody and the detecting capture antibody . In addition, the serum oxLp(a) level was quantified by a sandwich ELISA system using an oxLp(a)-specific monoclonal antibody (161E2) as both the solid-phase antibody and the detecting capture antibody (we think that the use of the same antibody can improve the specificity of the detection, because the specific epitope site is present at ≥ 2 locations in all apo(a) molecules), as previously described [5, 7]. This monoclonal antibody has been proven to react with only oxLp(a), but not native Lp(a) and LDL . For the measurement, the serum samples were placed in each well of the Nunc-polystyrene microplates coated with an anti-oxLp(a) monoclonal antibody. The plates were incubated for 1 hour at room temperature, and after washing, were incubated for 1 hour at room temperature with anti-oxLp(a) monoclonal antibody labelled with a peroxidase conjugate. After washing, 3,3',5,5'-tetra-methylbenzidine was added to each well, and the enzymatic reaction was thereafter carried out for 30 minutes at room temperature. After stopping the reaction, the absorbance was read at 450 nm. The concentration of oxLp(a) was calculated based on the concentration of the bovine serum albumin (BSA)-peptide that contributed 16 peptides per 1 molecule of BSA as a standard . The intra- and inter-assay coefficients of variation were 1.2% and 5.0%, respectively.
The CIMT of the common carotid arteries was measured ultrasonographically by a 10-MHz linear type B-mode probe (Aloka Co. Ltd., Japan). The CIMT, bilaterally measured in segments free of plaque (one at the thickest site and another at two other points [1 cm upstream and 1 cm downstream from the thickest site]), was averaged for 3 measurements.
The data are expressed as the means ± standard deviations or medians plus interquartile range. The correlations between the CIMT and the other variables, including Lp(a) and oxLp(a), were examined by Pearson's correlation test as well as a multiple linear regression analysis adjusted for the measured variables (age, gender, BMI, SBP, LDL-C, HDL-C, TG, glucose). Only the SBP was entered into a multiple linear regression analysis model because of its close collinearity with the DBP (r ≥ 0.7). In the multiple linear regression analysis, the values of TG, Lp(a), oxLp(a) and CIMT were calculated after a log-transformation because of their skewed distribution. In addition, the tertile categories of the serum Lp(a) or oxLp(a) levels as an explanatory variable and carotid atherosclerosis (defined as a CIMT of > 1.0 mm ) as a criterion variable were entered into a multivariate logistic regression model to estimate the odds ratio (OR) and 95% confidential interval (CI) for carotid atherosclerosis. The crude OR and OR adjusted for the measured variables (age, gender, BMI, SBP, DBP, LDL-C, HDL-C, TG, glucose) were determined. A P value of ≤ 0.05 was considered to be significant.
The clinical characteristics of the study subjects
64 ± 11
Body mass index, kg/m2
24.7 ± 3.8
Systolic blood pressure, mmHg
129 ± 14
Diastolic blood pressure, mmHg
79 ± 10
Low-density lipoprotein cholesterol, mmol/L
2.98 ± 0.75
High-density lipoprotein cholesterol, mmol/L
1.41 ± 0.38
6.44 ± 2.19
Oxidized Lp(a), nmol/L
The correlations between the CIMT and Lp(a) or oxidized Lp(a) level
For oxidized Lp(a)
0.415 (< 0.0001)**
0.426 (< 0.0001)**
0.423 (< 0.0001)**
Body mass index, kg/m2
- 0.019 (0.809)
- 0.015 (0.851)
Systolic BP, mmHg
Diastolic BP, mmHg
LDL cholesterol, mmol/L
- 0.018 (0.831)
HDL cholesterol, mmol/L
- 0.001 (0.993)
- 0.006 (0.943)
- 0.019 (0.822)
- 0.043 (0.616)
Oxidized Lp(a), nmol/L
In addition, a logistic regression analysis for carotid atherosclerosis using the tertile of the Lp(a) or oxLp(a) levels was carried out. There were 8 subjects with carotid atherosclerosis in the 1st tertile of Lp(a) (< 83 μmol/L [n = 46]), 11 subjects with carotid atherosclerosis in the 2nd tertile of Lp(a) (83-192 μmol/L [n = 45]) and 8 subjects with carotid atherosclerosis in the 3rd tertile of Lp(a) (> 192 μmol/L [n = 45]). The crude OR (95%CI) of Lp(a) was 1.0 (reference) in the 1st tertile, 1.53 (0.55-4.27, P = 0.41) in the 2nd tertile and 1.03 (0.35-3.02, P = 0.96) in the 3rd tertile. The multivariate-adjusted OR (95%CI) of Lp(a) was 1.0 (reference) in the 1st tertile, 1.80 (0.54-6.06, P = 0.34) in the 2nd tertile and 1.08 (0.31-3.82, P = 0.91) in the 3rd tertile. On the other hand, there were 5 subjects with carotid atherosclerosis in the 1st tertile of oxLp(a) (< 0.03 nmol/L [n = 46]), 8 subjects with carotid atherosclerosis in the 2nd tertile of oxLp(a) (0.03-0.08 nmol/L [n = 45]) and 14 subjects with carotid atherosclerosis in the 3rd tertile of oxLp(a) (> 0.08 nmol/L [n = 45]). The crude OR (95%CI) of oxLp(a) was 1.0 (reference) in the 1st tertile, 1.77 (0.53-5.90, P = 0.35) in the 2nd tertile and 3.70 (1.21-11.38, P = 0.02) in the 3rd tertile. The multivariate-adjusted OR (95%CI) of oxLp(a) was 1.0 (reference) in the 1st tertile, 2.72 (0.73-10.18, P = 0.14) in the 2nd tertile and 3.60 (1.01-12.92, P = 0.048) in the 3rd tertile. Therefore, the subjects with the highest tertile of oxLp(a), but not Lp(a), had a significantly and independently high OR for the presence of carotid atherosclerosis.
The present study showed that the serum oxLp(a) level was a significant, independent and positive measure of carotid atherosclerosis, as assessed by the CIMT, in comparison to the serum Lp(a) level, in asymptomatic subjects. A weak correlation between the Lp(a) and CIMT, and a relatively low level of Lp(a) (compared to an earlier study of a general Japanese population ) were observed in this study. This may be, in part, due to the studied population, all of whom were asymptomatic and of possibly good health, as well as due to the Lp(a) detection method using the antibody to a non-repeated segment of apo(a), which is not affected by apo(a) size polymorphisms . While the impact of oxLp(a) on carotid atherosclerosis was clear in the subjects with the highest tertile of oxLp(a), the circulating level of oxLp(a) was lower than that of Lp(a) and the correlation between the oxLp(a) and CIMT was not very strong as an overall finding. Therefore, the clinical relevance of the results will need to be confirmed in further studies. However, this finding obtained by the use of the CIMT is valuable because carotid atherosclerosis is a well-known clinical predictor of the CVD risk [15, 16]. Of note, the present findings suggest that high serum levels of oxLp(a) may be associated with accelerated atherosclerosis, which provides important information for obtaining a better understanding of the different atherogenic roles played by oxLp(a) in comparison to Lp(a), in addition to the earlier knowledge about the clinical associations among Lp(a), oxLp(a) and atherosclerotic manifestations [6, 8].
The precise reason for the association between the serum oxLp(a) and CIMT in this study was unclear, although a possible mechanism has been suggested. One experimental study reported the generation of O2- (promoting oxidative stress) in oxLp(a)-treated rabbit renal arteries, which could lead to endothelial dysfunction (this occured in the oxLp(a)-, but not native Lp(a)-, treated rabbits) . One clinical study showing a significant and positive correlation between the oxLp(a) and pulse wave velocity in hypertensive patients assumed that the oxidative status of hypertension could contribute to that correlation . Another histochemical study on human carotid arteries reported the presence of oxLp(a) in the endothelial cells and subendothelial layers, indicating that native Lp(a) is initially oxidized or that oxLp(a) is initially taken up from the blood into the endothelial cells and subendothelial layers . Moreover, that study implicated oxLp(a) as having more involvement, relative to native Lp(a), in the progression of arthrosclerosis, based on the abundant presence of oxLp(a) in the synthetic phase vascular smooth muscle cells . In general, oxidative stress induces increases in the CIMT, and the increased CIMT can further enhance the oxidative stress, leading to a vicious cycle (this cycle may be essentially pronounced during the progressive stage of arthrosclerosis) . In addition, it is thought that Lp(a) can be atherogenic in relation to oxidized molecules, such as oxidized phospholipids, under the oxidative milieu, where the oxidation of Lp(a) may be promoted . In this context, we hypothesize that once oxLp(a) is present, it induces an oxidative condition, and this condition increases the CIMT, and a vicious cycle of oxLp(a)-CIMT elevation occurs as a result.
There are several limitations to this study. The study population was restricted to asymptomatic subjects, not an obviously diseased population. The cross-sectional design of the study did not clearly elucidate the cause-and-effect on the results. In addition, the residual confounding factors that can affect the oxidative status and/or the oxidation of lipoproteins (i.e., dietary factors) were not available in the study. Therefore, future studies with different populations, prospective designs and the inclusion of many confounders will be necessary to establish our findings.
In summary, the serum oxLp(a) was more significantly, independently and positively correlated with the CIMT than the serum Lp(a), in asymptomatic middle-aged and older subjects. This finding seems to be important for obtaining a better understanding of the different atherogenic roles played by oxLp(a) in comparison to Lp(a) in the pathogenesis of atherosclerosis. Further studies are required to determine the observed relationship and to clarify the biological mechanisms involved in this relationship.
This study was supported in part by a Grant-in-Aid for the Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (K.K) and the Foundation for the Development of the Community, Japan.
- Holvoet P: Oxidized LDL and coronary heart disease. Acta Cardiol. 2004, 59: 479-484. 10.2143/AC.59.5.2005219View ArticlePubMedGoogle Scholar
- Marcovina SM, Koschinski ML: Lipoprotein(a) as a risk factor for coronary artery disease. Am J Cardiol. 1998, 82: U57-66. 10.1016/S0002-9149(98)00954-0.View ArticleGoogle Scholar
- , Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG, Danesh J: Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009, 302: 412-423.View ArticleGoogle Scholar
- Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, Witztum JL, Berger PB: Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med. 2005, 353: 46-57. 10.1056/NEJMoa043175View ArticlePubMedGoogle Scholar
- Yamada S, Morishita R, Nakamura S, Ogihara T, Kusumi Y, Sakurai I, Kubo N, Sakurabayashi I: Development of antibody against epitope of lipoprotein(a) modified by oxidation: evaluation of new enzyme-linked immunosorbent assay for oxidized lipoprotein(a). Circulation. 2000, 102: 1639-1644.View ArticlePubMedGoogle Scholar
- Morishita R, Ishii J, Kusumi Y, Yamada S, Komai N, Ohishi M, Nomura M, Hishida H, Niihashi M, Mitsumata M: Association of serum oxidized lipoprotein(a) concentration with coronary artery disease: potential role of oxidized lipoprotein(a) in the vasucular wall. J Atheroscler Thromb. 2009, 16: 410-418. 10.5551/jat.No224View ArticlePubMedGoogle Scholar
- Kotani K, Yamada S, Uurtuya S, Yamada T, Taniguchi N, Sakurabayashi I: The association between blood glucose and oxidized lipoprotein(a) in healthy young women. Lipids Health Dis. 2010, 9: 103-PubMed CentralView ArticlePubMedGoogle Scholar
- Umahara T, Uchihara T, Yamada S, Hashimoto T, Akimoto J, Haraoka J, Iwamoto T: Differential expression of oxidized/native lipoprotein(a) and plasminogen in human carotid and cerebral artery plaques. Atherosclerosis. 2011, 215: 392-398. 10.1016/j.atherosclerosis.2010.10.048View ArticlePubMedGoogle Scholar
- Zioncheck TF, Powell LM, Rice GC, Eaton DL, Lawn RM: Interaction of recombinant apolipoprotein(a) and lipoprotein(a) with macrophages. J Clin Invest. 1991, 87: 767-771. 10.1172/JCI115079PubMed CentralView ArticlePubMedGoogle Scholar
- Riis-Hansen P, Kharazmi A, Jauhiainen M, Ehnholm C: Induction of oxygen free radical generation in human monocytes by lipoprotein(a). Eur J Clin Invest. 1994, 24: 497-499.View ArticlePubMedGoogle Scholar
- Galle J, Bengen J, Schollmeyer P, Wanner C: Impairment of endothelium-dependent dilation in rabbit renal arteries by oxidized lipoprotein(a). Circulation. 1995, 92: 1582-1589.View ArticlePubMedGoogle Scholar
- Beaudeux JL, Césarini ML, Gardès-Albert M, Maclouf J, Merval R, Esposito B, Peynet J, Tedqui A: Native and gamma radiolysis-oxidized lipoprotein(a) increase the adhesiveness of rabbit aortic endothelium. Atherosclerosis. 1997, 132: 29-35. 10.1016/S0021-9150(97)00073-7View ArticlePubMedGoogle Scholar
- Ren S, Man RY, Angel A, Shen GX: Oxidative modification enhances lipoprotein(a)-induced overproduction of plasminogen activator inhibitor-1 in cultured vascular endothelial cells. Atherosclerosis. 1997, 128: 1-10. 10.1016/S0021-9150(96)05971-0View ArticlePubMedGoogle Scholar
- Komai N, Morishita R, Yamada S, Oishi M, Iguchi S, Aoki M, Sasaki M, Sakurabayashi I, Higaki J, Ogihara T: Mitogenic activity of oxidized lipoprotein (a) on human vascular smooth muscle cells. Hypertension. 2002, 40: 310-314. 10.1161/01.HYP.0000029974.50905.B4View ArticlePubMedGoogle Scholar
- Kawamoto R, Tomita H, Oka Y, Ohtsuka N, Kamitani A: Metabolic syndrome and carotid atherosclerosis: role of elevated blood pressure. J Atheroscler Thromb. 2005, 12: 268-275. 10.5551/jat.12.268View ArticlePubMedGoogle Scholar
- Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M: Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007, 115: 459-467. 10.1161/CIRCULATIONAHA.106.628875View ArticlePubMedGoogle Scholar
- Yamada S, Inoue K, Morishita R, Ogihara T, Kubono K, Kubo N, Abe A, Sakurabayashi I: A new Lp(a) assay that is unaffected by apo(a) size polymorphism. Clin Chim Acta. 1999, 287: 29-43. 10.1016/S0009-8981(99)00119-9View ArticlePubMedGoogle Scholar
- Gotoh T, Kuroda T, Yamasawa M, Nishinaga M, Mitsuhashi T, Seino Y, Nagoh N, Kayaba K, Yamada S, Matsuo H, Hosoe M, Itoh Y, Kawai T, Igarashi M, Shimada K: Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study). Am J Cardiol. 1995, 76: 928-932. 10.1016/S0002-9149(99)80263-XView ArticlePubMedGoogle Scholar
- Madamanchi NR, Hakim ZS, Runge MS: Oxidative stress in atherogenesis and arterial thrombosis: the disconnect between cellular studies and clinical outcomes. J Thromb Haemost. 2005, 3: 254-267. 10.1111/j.1538-7836.2004.01085.xView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.